The South African Health Products Regulatory Authority (SAHPRA) announced on Thursday that Merck’s COVID-19 therapy tablet Molnupiravir had been approved for usage.
Pfizer had submitted an application for its COVID-19 tablet, Paxlovid, which was under consideration, according to SAHPRA. “The approval of Molnupiravir for compassionate use adds to the treatment options for COVID-19,” said SAHPRA Chief Executive Boitumelo Semete-Makokotlela.
Molnupiravir is only recommended for patients aged 18 and up, according to SAHPRA. It granted permission for the importation of a restricted number of molnupiravir capsules for a six-month term, subject to certain criteria.
World News
Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn»TDPel Media News« »For Breaking News«| »For Featured«| »For Biographies« »For Lifestyle« »For Lottery« »For Fashion« »For Politics« »For Business« »For Entertainment« »For Wellness and Fitness« »For Religion« »For Science« »For Sports« »For Technology« »For Health« »For TDPelTV« »For World News« »TDPel Media News« »For TDPel Community« »TDPel Media News« »For Breaking News«| »For Featured«| »For Biographies« »For Lifestyle« »For Lottery« »For Fashion« »For Politics« »For Business« »For Entertainment« »For Wellness and Fitness« »For Religion« »For Science« »For Sports« »For Technology« »For Health« »For TDPelTV« »For World News« »TDPel Media News« »For TDPel Community«